Biomedical subjects

David Sandler

Publications and source records attributed to David Sandler.

2 recordsLinked to original sources

PubMed2003

Intraperitoneal pocket for left ventricular assist device placement.

BACKGROUND: Implantation of the HeartMate Implanted Pneumatic or Vented Electric Ventricular Assist Device requires that the pump be implanted either in the peritoneal cavity or in the abdominal wall. Both sites have been problematic. METHODS: We describe a new technique in which an intraperitoneal pocket is created, using Gore-Tex Dual Mesh Plus Biomaterial with Holes, to contain the ventricular assist device. This shields the ventricular assist device from the peritoneal contents and avoids abdominal wall dissection. Thirty consecutive patients who underwent implantation using this technique were compared with 16 patients who underwent implantation before this technique was in use. RESULTS: Thirty consecutive patients underwent implantation, and 2 of those patients underwent re-implantation because of device failure (16/30 HeartMate Implanted Pneumatic, 14/30 HeartMate Vented Electric, and 2/14 HeartMate Vented Electric replaced with the HeartMate Implanted Pneumatic). Twenty-five patients have undergone explantation. Pocket infections in patients who have had implanted devices for >1 month decreased from 4 of 13 before the pockets were used to 1 of 25 with the intraperitoneal pockets (Fisher's exact test p = 0.038). Two hernia repairs were required after explantation when the biomaterial pocket was used. A decrease in return to surgery for bleeding was noted after the pocket was used (7/16 without the pocket and 3/32 with the pocket; Fisher's exact test, p = 0.010). CONCLUSIONS: Bleeding complications and pocket infections decreased in this early experience. Further study is necessary to confirm the apparent decrease in complication rate by using this new technique in this small cohort of patients.

Device Removal↗

PubMed2002

Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol.

BACKGROUND: Although used for more than 20 years, optimal dosing strategies of most immunosuppressants have never been determined. Tacrolimus, one of the newer agents used in solid-organ transplantation, is gaining increasing popularity because of its ability to reverse refractory rejection in cyclosporine-treated patients and its favorable side-effect profile. As with many other immunosuppressive agents, absorption and metabolism vary between individuals, which complicates dosing. METHODS: We hypothesized that a 1-mg dose of tacrolimus may be used to gauge each patient's metabolism. A novel dosing scheme was evaluated to establish the safety and efficacy of this approach. Outcomes were incidence of renal insufficiency and treatment efficacy as assessed by the rejection grade on the first endomyocardial biopsy. RESULTS: The risk of renal insufficiency was low, with only a 3% rise in creatinine at 7 days posttransplant. The risk of renal insufficiency was highest during the first 3 days of tacrolimus therapy, and the change in tacrolimus level during this time was identified as the single best predictor of renal insufficiency. From days 4 to 7, the rise in tacrolimus level had much less influence on renal function. Ninety-two percent of patients had a low- or intermediate-grade first cardiac biopsy. CONCLUSIONS: It was shown that this conservative initial dosing approach, which guarantees renal safety, is not associated with an increased risk of allograft rejection. We conclude that administration of tacrolimus via a tailored protocol soon after transplantation ensures a safe and effective means of immunosuppression.

Adult↗